THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING

Genzyme sheds division to focus on biotech core

$925m sale may put pressure on Sanofi to raise bid

By Robert Weisman
Globe Staff / September 14, 2010

E-mail this article

Invalid E-mail address
Invalid E-mail address

Sending your article

Your article has been sent.

Text size +

Genzyme Corp.’s agreement to sell its genetics testing business for $925 million could step up pressure on suitor Sanofi Aventis SA to buy the Cambridge biotechnology company before it unloads other assets, industry watchers said yesterday. (Full article: 810 words)

This article is available in our archives:

Globe Subscribers

FREE for subscribers

Subscribers to the Boston Globe get unlimited access to our archives.

Not a subscriber?

Non-Subscribers

Purchase an electronic copy of the full article. Learn More

  • $9.95 1 month archives pass
  • $24.95 3 months archives pass
  • $74.95 1 year archives pass